A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Completed · Phase 3 · Has a placebo group

Conditions studied: Schizophrenia

In brief

A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 13 years old -65 years old who have been diagnosed with schizophrenia.

Key facts

Study ID: NCT04072354
Run by: Otsuka Pharmaceutical Development & Commercialization, Inc.
People needed: 463
Starts: 2019-09-17
Expected to finish: 2023-09-12
Last updated by the study team: 2026-05-28

Who can join

Age: 13 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female subject between 13 to 65 years of age (inclusive) at the time of consent.
Subject or subjects parent/legal guardian [adolescents] must give written informed consent and privacy authorization prior to participate in the study; adolescents must also provide informed assent..
Subject meets DSM-5 criteria for schizophrenia as established by clinical interview at screening
Subject must have a CGI-S score ≥ 4
Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content
Subject has an acute exacerbation of psychotic symptoms (persisting no longer than 2 months prior to providing informed consent).
Subject has marked deterioration of functioning in one or more areas.
Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, ECG, and clinical laboratory values.

You may not qualify if…

Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months or lifetime history of significant substance abuse that in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact of the brain or other body systems, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms are not the primary focus of treatment.
Subject is at significant risk of harming self, others, or objects based on Investigator's judgment.
Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study:
Female subject who is pregnant or lactating
Subject has any clinically significant abnormal laboratory value(s) at Screening as determined by the investigator.

Where it is running

Research Site — Anaheim, California, United States
Research Site — Bellflower, California, United States
Research Site — Lemon Grove, California, United States
Research Site — Long Beach, California, United States
Research Site — Montclair, California, United States
Research Site — Pico Rivera, California, United States
Research Site — San Diego, California, United States
Research Site — Hollywood, Florida, United States
Research Site — Hollywood, Florida, United States
Research Site — Miami Springs, Florida, United States
Research Site — Atlanta, Georgia, United States
Research Site — Atlanta, Georgia, United States
Research Site — Decatur, Georgia, United States
Research Site — Gaithersburg, Maryland, United States
Research Site — Flowood, Mississippi, United States
Research Site — Dayton, Ohio, United States
Research Site — Austin, Texas, United States
Research Site — Pazardzhik, Bulgaria
Research Site — Pleven, Bulgaria
Research Site — Sofia, Bulgaria
Research Site — Sofia, Bulgaria
Research Site — Veliko Tarnovo, Bulgaria
Research Site — Vratsa, Bulgaria
Research Site — Bello, Antioquia, Colombia
Research Site — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.